How to Use an ISO 13485 Certificate for Overseas Registration of Rehabilitation Equipment

ISO 13485 certification demonstrates that a rehabilitation equipment manufacturer operates a compliant quality management system, but it does not replace a medical device marketing authorization in the target country. To use it correctly, first confirm whether your product qualifies as a medical device in the destination market and determine its risk classification; then identify the appropriate registration pathway and applicant; include the ISO 13485 certificate as quality-system evidence within the registration dossier, supplemented with technical documentation, risk management, performance/clinical evaluation, locally adapted labeling, and a designated local agent or authorized representative.

Published: August 18, 2026 | Updated: August 18, 2026

Key Takeaways

For rehabilitation equipment manufacturers pursuing overseas registration, the ISO 13485 certificate is evidence of your quality management system, but it cannot replace a medical device product registration certificate in the target country. The correct approach is: first determine whether the product is a medical device in the target country and its risk classification; then identify the applicable registration pathway and applicant; include the ISO 13485 certificate as quality-system compliance evidence in the registration dossier, supplemented with product technical documentation, risk management reports, performance verification or clinical evaluation, locally adapted labeling and instructions for use, and designate a local agent or authorized representative.

Common risks include assuming the certificate alone permits market launch, overlooking mismatches between certificate scope and product models, lacking quality-system operational records, failing to perform local-language translation and agent authorization, and missing post-market maintenance. Companies should conduct a gap analysis early in the project, assess the reusability of existing NMPA, CE, FDA, MDSAP, and other documentation, and focus on core-file reuse and localization for GHWP member countries and markets in Southeast Asia, the Middle East, and Latin America. This improves registration success rates and reduces the risk of requests for amendment.

For Chinese medical device companies, a prudent approach is to first conduct product classification and documentation gap assessments, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in the target market usually affects technical documentation, authorized representatives, importer coordination, label language, quality-system evidence, and subsequent change maintenance. If you only focus on 'which documents to submit' at the outset, you may encounter requests for amendment or rework in areas such as model coverage, evidence-chain consistency, label claims, and certificate control.

AIMEILI recommends that companies plan this issue within the context of GHWP member countries and a multi-country access strategy, using a set of reusable core technical documents to support localization in different markets, rather than recreating documentation for each country on an ad hoc basis.

Applicable Scenarios and Core Issues

After obtaining an ISO 13485 certificate, rehabilitation equipment companies often mistakenly believe the certificate can be used directly for overseas market access. In reality, the ISO 13485 certificate is merely a conformity statement for your quality management system, confirming that you have established and operate a system covering medical device design and development, production, storage, installation, and service. It is not a product registration certificate and does not replace the marketing authorization issued by the target country's medical device regulatory authority.

Rehabilitation equipment includes physical therapy devices, rehabilitation training devices, walking aids, wheelchairs, orthoses, prostheses, assessment equipment, and more. Regulatory classification varies significantly across countries and regions. A product classified as Class I in Country A may be Class II or III in Country B, or may not be regulated as a medical device at all. You must first confirm the product's regulatory status in the target market, then determine the actual role of the ISO 13485 certificate in the registration process.

In overseas registration projects, the ISO 13485 certificate is typically submitted as part of the system documentation to prove that your quality management system meets internationally recognized medical device system standards. However, target-country regulators also require substantive evidence of product safety and effectiveness, including performance testing, risk management, clinical evaluation, labeling, and post-market surveillance. Only by placing the ISO 13485 certificate in the correct evidentiary position can you avoid rejection or requests for amendment of your registration application.

Registration Decision Logic

When facing overseas registration, you should follow a clear logical sequence rather than simply submitting the ISO 13485 certificate. First, determine whether the product falls under the target country's medical device regulatory scope. For example, some Southeast Asian countries may treat certain rehabilitation training devices as general fitness equipment, while the EU may regulate them as Class I or IIa medical devices. If the product is not a medical device, the ISO 13485 certificate need not be included in the registration dossier.

Second, determine the product's risk classification and registration pathway. Different countries have completely different requirements for Class I, II, and III products. Class I may only require notification or self-declaration, while Class II and above generally require substantive review, technical documentation evaluation, or even on-site inspection. Based on the classification, you should decide whether to file independently, engage a local agent, or leverage an existing CE or FDA pathway for conversion.

Third, assess the reusability of existing certificates and documentation. Existing NMPA registrations, CE technical files, FDA 510(k) or QSR 820 system records, MDSAP audit reports, ISO 13485 certificates, and other materials can provide foundational support. However, these materials cannot be transferred directly. They must be adapted to the target country's regulatory requirements and clinical terminology.

Fourth, check for gaps against target-country requirements, including whether the technical file covers product specifications, whether performance verification meets local standards, whether the risk management report complies with ISO 14971 and reflects the local use environment, whether clinical evaluation or clinical evidence is sufficient, whether labeling and instructions need local-language versions, whether a local agent and authorized representative have been appointed, and whether post-market maintenance and adverse event reporting mechanisms are in place. Only after completing these assessments can you determine the specific use of the ISO 13485 certificate in your registration strategy.

Documentation and Evidence

The ISO 13485 certificate commonly serves as quality-system compliance evidence in overseas registration, but you cannot submit just a single certificate page. Regulators typically require the certificate annex, a description of the certification scope, proof of the certifying body's accreditation, and audit records from within the certificate's validity period.

A complete quality-system evidence package typically includes: the original ISO 13485 certificate and its certified annex to demonstrate the product types and manufacturing sites covered by the quality management system; a quality manual and required procedure documents to explain how the system operates; internal audit reports and management review records to demonstrate continual improvement; and annual or semi-annual surveillance audit reports from the certifying body to confirm the certificate remains valid.

In addition to system evidence, you must prepare product technical documentation for the registration application, including product design descriptions, specifications, manufacturing process information, sterilization or microbial control measures (if applicable), and packaging verification. The risk management report should be based on ISO 14971, identifying risks related to intended use and explaining whether residual risks are acceptable. Performance verification and test reports should refer to standards applicable in the target country, such as the IEC 60601 series for electrical safety, ISO 10993 for biocompatibility, and specific performance standards for rehabilitation equipment.

Clinical evaluation documentation is also a mandatory component in many countries. You need to determine whether the product is exempt from clinical trials, whether it can be validated through literature data or equivalent-device reasoning, or whether local clinical data must be submitted. The clinical evaluation report should include the literature search strategy, data assessment methodology, residual clinical risks, and conclusions on benefit-risk. Labels and instructions for use must be translated into the local language and prepared according to the target country's formatting requirements, including symbols, warnings, usage instructions, and maintenance information.

Furthermore, nearly all non-local manufacturers must appoint a local agent or authorized representative. The agent's authorization document, a description of the agent's responsibilities, and the registration certificate holder's information must be clear. You should also establish a post-market surveillance plan, including complaint handling, adverse event reporting, product recall procedures, and periodic update reports. These elements must be reflected in the registration dossier.

Common Mistakes

• Submitting the ISO 13485 certificate as if it were the product registration certificate itself, believing the certificate alone permits sales in the target country. This is the most common mistake.
• Overlooking consistency between the ISO 13485 certificate's scope and the product models. If the certificate scope covers only some models or does not cover the intended manufacturing site, the submission will be deemed non-compliant.
• Failing to submit surveillance audit records from within the certificate's validity period, leaving regulators unable to confirm that the system remains in good standing.
• Submitting the certificate in Chinese or English without translation into the target country's official language or without notarization/apostille, causing failure during the formalities review.
• Not conducting a gap analysis against target-country regulations, and submitting CE or FDA technical files unchanged to GHWP countries, lacking explanations of local standard differences.
• Ignoring local agent and authorized representative requirements, leading to disqualification of the applicant.
• Lacking post-market surveillance and adverse event reporting systems; despite submitting the ISO 13485 certificate, no evidence of annual system operation data is provided.
• Failing to recognize classification differences across countries, incorrectly applying another country's risk level and registration pathway, resulting in a fundamentally wrong submission path.

Company Preparation Checklist

• Confirm the target country's regulatory classification and product risk class, and establish classification-basis documentation.
• Verify the ISO 13485 certificate's validity period, the referenced certification standard version, covered products, and manufacturing sites; ensure the certificate scope covers the intended product.
• Collect quality-management-system operational evidence, including internal audit reports, management review reports, annual surveillance audit reports, and records of corrective actions for non-conformities.
• Organize product technical documentation, including design documents, specifications, manufacturing process, packaging, and draft labels and instructions for use.
• Prepare the risk management report, updating the risk analysis for the target country's user population and clinical environment.
• Complete performance verification or test reports using standards and methods accepted by the target country.
• Assess clinical evaluation requirements; prepare the clinical evaluation report or collect supporting literature data.
• Develop a localization plan for translating labels and instructions for use, and have the local regulatory consultant or agent review them.
• Select and appoint a local agent or authorized representative, signing the agency agreement and power of attorney.
• Establish post-market surveillance procedures, including complaint handling, adverse events, product updates, and registration change management.
• Inventory existing NMPA, CE, FDA, MDSAP, and other documentation; create a gap list separating reusable files from files that must be redone.
• Develop a registration project timetable and budget, allocating time for amendments and communications with regulators.

AIMEILI's Perspective

From the perspective of a regulatory consultancy, the most easily misjudged point for rehabilitation equipment companies is believing that the value of the ISO 13485 certificate can cover the substantive review of product registration. In reality, the ISO 13485 certificate is only one of the stepping stones to enter the overseas registration threshold. What target-country regulators truly care about is whether the product is safe and effective, and whether the company can continually ensure product quality. Both of these require substantial technical evidence and operational records.

We advise companies not to rush to pay registration fees early in the project, but to first conduct a regulatory gap analysis for the target country. By comparing existing product documentation with target-country requirements, you can quickly identify missing items and avoid multiple amendments after submission. This is especially relevant for GHWP member countries, Southeast Asia, the Middle East, and Latin America, where accepted international standards are often based on ISO, IEC, and ISO 14971, but registration procedures, language requirements, and local agent responsibilities vary significantly.

Which documents can be reused? System-related documents, such as quality manuals, internal audit records, and management review records, can usually be reused after translation and reasonable adjustment. The risk management framework based on ISO 14971 can be reused, but the risk evaluation must be updated with local clinical use data. Basic performance test reports can also be reused, provided the test standards are accepted by the target country and the product technical specifications have not changed. What must be localized? Registration application forms and administrative documents must use the local language and forms. Labels and instructions for use must be translated and must comply with local medical device labeling regulations. Clinical evaluation must be re-argued using local population and epidemiological data. Documents for the local agent and authorized representative must be drafted and notarized locally.

Local agents and certificate control also deserve special attention. Many companies neglect oversight of their local agent, resulting in a registration certificate held in the certificate holder's name but without control over changes and renewals. If the ISO 13485 certificate undergoes changes in address, quality manager, standard version, or certification scope, the local agent must be promptly notified to update the registration dossier; otherwise, the certificate may be suspended or withdrawn. Renewal should also be planned in advance because in most countries the expiry date of the ISO 13485 certificate affects the maintenance cycle of the registration certificate. You need to coordinate with the certifying body and the local agent.

When it comes to multi-country registration, our recommendation is to establish a common set of base technical documents and then have each target-country regulatory team tailor them locally. This reduces the frequency of repetitive compilation and amendments, while also unifying the evidence chain under a common standard. In this system, the ISO 13485 certificate serves as the primary quality-system evidence, and its associated audit records, quality data, and declarations of conformity can be reused across multiple countries. Only by viewing the issue from the perspective of a complete compliance system can companies truly leverage the certificate.

Common Follow-up Questions

Do ISO 13485 certificates need notarization and translation?

Most overseas registration processes require the ISO 13485 certificate to be provided in the official language of the target country. English certificates are accepted in some countries, but in many Latin American countries, Middle Eastern countries, and some GHWP member states, they must be translated into the local language and notarized or authenticated. Companies should confirm the specific translation and notarization requirements with the target-country regulatory authority to avoid rejection due to formality issues.

What if the ISO 13485 certificate's validity period is shorter than the product registration cycle?

The ISO 13485 certificate typically has a three-year validity period, but product registration review can exceed one year or even longer. As long as the certificate is valid at the time of dossier submission, most regulators accept that the certificate remains valid during the registration process. However, you must continue to undergo surveillance audits and complete renewal before the certificate expires. If the certificate is suspended during review or expires without renewal, regulators may require a new certificate or initiate a re-review. We recommend arranging the renewal audit at least six months before the certificate expires.

With an existing CE certificate, what additional steps are needed for other markets?

CE technical documentation can serve as a base, but it cannot be used directly for other markets. The US FDA, Southeast Asia, the Middle East, and other regions have different data standards, test methods, classifications, and clinical evaluation requirements. Even with a CE certificate, you still need to supplement performance test reports required by the target country, update the risk management report to reflect the local use environment, translate and rewrite labels and instructions for use, and confirm compliance with local agent and registration pathway requirements. Additionally, the certificate holder information on the ISO 13485 certificate, the CE certificate, and the local registration certificate must be consistent; otherwise, the evidence chain will be broken.

Further Reading

• How to Group Multiple Models for Overseas Registration of Monitoring Equipment?
• How to Group Multiple Models for Overseas Registration of Rehabilitation Equipment?
• How to Conduct Post-Market Surveillance for Overseas Registration of Rehabilitation Equipment?
• When Should Registration Changes Be Reported for Overseas Rehabilitation Equipment Registration?
• What Should Be Prepared Before Renewing Overseas Registration of Rehabilitation Equipment?
• What to Do When Quality System Certificates Are Inconsistent in Overseas Rehabilitation Equipment Registration?

Content Review and Applicability

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory agencies, international organizations, standards bodies, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Applicability: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target-country regulatory authority, testing conclusions, or legal advice.